Clinical Trial Highlights

Core operating income to consolidated net profit €m H1 2023 H1 2022 Change Core Operating Income 523.2 568.0 -7.9% Amortization of intangible assets (90.7) (46.6) 94.6% Restructuring and other operating (125.0) (20.0) n/a expense Impairment losses (11.9) 0.0 n/a IFRS Operating Income 295.6 501.3 -42.2% Net financing expenses (12.0) (9.5) -27.0% Other financial income (22.1) (0.5) n/a Income taxes and other (66.4) (109.1) -39.2% Net profit from discontinued operations 0.0 12.1 n/a IFRS Consolidated Net Profit Core earnings per share 195.1 394.3 -50.5% €4.73 €5.06 -6.6% IPSEN Innovation for patient care All growth rates are at actual exchange rates. Amortization of intangible assets Increase mainly from Bylvay & Tazverik Restructuring & other operating expense Mainly related to Albireo integration & transaction costs, other transformation programs and discontinuation of clinical trials Core earnings per share In line with core operating income with core effective tax rate at 20.4% 13

View entire presentation